Further validation of LABORAS™ using various dopaminergic manipulations in mice including MPTP-induced nigro-striatal degeneration

Journal of Neuroscience Methods

Volumn 156, Issue 1-2, 2006, Pages 218-227

  Quinn, Leann P ^a   Stean, Tania O ^a   Chapman, Helen ^a   Brown, Matthew ^a   Vidgeon Hart, Martin ^a   Upton, Neil ^a   Billinton, Andrew ^a   Virley, David J ^a  

^a GLAXOSMITHKLINE   (United Kingdom)

Author keywords

Automatic behaviour registration; Dopamine agonists; Dopamine antagonists; l DOPA; Mice; MPTP

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; 8 CHLORO 2,3,4,5 TETRAHYDRO 3 METHYL 5 PHENYL 1H 3 BENZAZEPIN 7 OL HYDROGEN MALEATE; AMPHETAMINE; APOMORPHINE; DOPAMINE RECEPTOR STIMULATING AGENT; HALOPERIDOL; LEVODOPA; SODIUM CHLORIDE; DOPAMINE RECEPTOR BLOCKING AGENT;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUTOANALYZER; BEHAVIOR DISORDER; COMPARATIVE STUDY; CONTROLLED STUDY; DOPAMINERGIC ACTIVITY; DOSE RESPONSE; DRUG EFFECT; GROOMING; INFORMATION PROCESSING; LABORATORY ANIMAL BEHAVIOUR OBSERVATION REGISTRATION AND ANALYSIS SYSTEM; LOCOMOTION; MALE; MOTOR ACTIVITY; MOUSE; NEUROMODULATION; NONHUMAN; OBSERVATIONAL STUDY; PRIORITY JOURNAL; RELIABILITY; STRIATONIGRAL DEGENERATION; VALIDATION STUDY; ANIMAL; AUTOMATION; BRAIN LEVEL; C57BL MOUSE; CHEMICALLY INDUCED DISORDER; ELECTROCHEMISTRY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HYPERKINESIA; IMMUNOHISTOCHEMISTRY; INSTRUMENTATION; NEOSTRIATUM; NERVE DEGENERATION; PATHOLOGY; PSYCHOLOGICAL ASPECT; PSYCHOLOGY; REPRODUCIBILITY; SUBSTANTIA NIGRA;

(R)-2,3,4,5-TETRAHYDRO-8-CHLORO-3-METHYL-5-PHENYL-1H-3-BENZAZEPIN-7-OL; 1-METHYL-4-PHENYL-1,2,3,6-TETRAHYDROPYRIDINE; AMPHETAMINE; ANIMALS; APOMORPHINE; AUTOMATION; BEHAVIOR, ANIMAL; BRAIN CHEMISTRY; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DOPAMINE AGENTS; DOPAMINE AGONISTS; DOPAMINE ANTAGONISTS; DOSE-RESPONSE RELATIONSHIP, DRUG; ELECTROCHEMISTRY; HALOPERIDOL; HYPERKINESIS; IMMUNOHISTOCHEMISTRY; MALE; MICE; MICE, INBRED C57BL; MOTOR ACTIVITY; NEOSTRIATUM; NERVE DEGENERATION; PSYCHOLOGY, EXPERIMENTAL; REPRODUCIBILITY OF RESULTS; SUBSTANTIA NIGRA;

EID: 33747261567     PISSN: 01650270     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jneumeth.2006.03.013     Document Type: Article

References (39)

1. Arai N., Misugi K., Goshima Y., and Misu Y. Evaluation of a 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated C57 black mouse model of parkinsonism. Brain Res 515 (1990) 57-63
2. Berardelli A., Rothwell J.C., Thompson P.D., and Hallett M. Pathophysiology of bradykinesia in Parkinson's disease. Brain 124 (2001) 2131-2146
3. Bezard E., and Gross C.E. Compensatory mechanisms in experimental and human parkinsonism: towards a dynamic approach. Prog Neurobiol 55 (1998) 93-116
4. Chia L.G., Ni D.R., Cheng L.J., Kuo J.S., Cheng F.C., and Dryhurst G. Effects of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine and 5,7-dihydroxytryptamine on the locomotor activity and striatal amines in C57BL/6 mice. Neurosci Lett 218 (1996) 67-71
5. Di Chiara G., Porceddu M.L., Vargiu L., Argiolas A., and Gessa G.L. Evidence of dopamine receptors mediating sedation in the mouse brain. Nature 264 (1976) 564-567
6. Franklin K.B.J., and Paxinos G. The mouse brain in stereotaxic coordinates (1997), Academic Press, San Diego
7. Fredriksson A., and Archer T. MPTP-induced behavioural and biochemical deficits: a parametric analysis. J Neural Transm 7 (1994) 123-132
8. Fredriksson A., Eriksson P., and Archer T. MPTP-induced deficits in motor activity: neuroprotective effects of the spintrapping agent, α-phenyl-tert-butyl-nitrone (PBN). J Neural Transm 104 (1997) 579-592
9. Gronan R.J. Time and dose influences on the behavioural effects of l-DOPA and 5-hydroxytryptophan after inhibition of extracerebral decarboxylase. Pharmacol Biochem Behav 3 (1975) 161-166
10. Heikkila R.E., Hess A., and Duvoisin R.C. Dopaminergic neurotoxicity of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in mice. Science 224 (1984) 1451-1453
11. Irifune M., Nomoto M., and Fukuda T. Effects of GBR12909 on locomotor activity and dopamine turnover in mice: comparison with apomorphine. Eur J Pharmacol 272 (1995) 79-85
12. Johnson A.M., Loew D.M., and Vigouret J.M. Stimulant properties of bromocriptine on central dopamine receptors in comparison to apomorphine, (+)-amphetamine and l-DOPA. Br J Pharmacol 56 (1976) 59-68
13. Jonkers N., Sarre S., Ebinger G., and Michotte Y. Benserazide decreases central AADC activity, extracellular dopamine levels and levodopa decarboxylation in striatum of the rat. J Neural Transm 108 (2001) 559-570
14. Matsumoto K., Bing C., Sasaki K., and Watanabe H. Methamphetamine- and apomorphine-induced changes in spontaneous motor activity using a new system to detect and analyse motor activity in mice. J Pharmacol Meth 24 (1990) 111-119
15. Nishi K., Kondo T., and Narabayashi H. Destruction of norepinephrine terminals in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated mice reduces locomotor activity induced by l-DOPA. Neurosci Lett 123 (1991) 244-247
16. Ogawa N., Mizukawa K., Hirose Y., Kajita S., Ohara S., and Watanabe Y. MPTP-induced parkinsonian model in mice: biochemistry, pharmacology and behaviour. Eur Neurol 26 (1987) 16-23
17. 1 agonist C-APB in mice. Psychopharmacology 145 (1999) 237-250
18. Quinn L.P., Stean T., Trail B., Wilson A., Bulthuis R., and Upton N. LABORAS™ system validation: using orexin-A induced grooming. Monitoring molecules in neuroscience. Proceedings of the ninth international conference on in vivo methods (2001) 31-32
19. Quinn L.P., Stean T.O., Trail B., Duxon M.S., Stratton S.C., Billinton A., et al. LABORAS™: initial pharmacological validation of a system allowing continuous monitoring of laboratory rodent behaviour. J Neurosci Meth 130 (2003) 83-92
20. Quinn L.P., Grundy R.I., Campbell C.A., Collier S., Lawman A., Stean T.O., et al. A novel behavioural registration system LABORAS™ and the social interaction paradigm detect long-term functional deficits following middle cerebral artery occlusion in the rat. Brain Res 1031 (2005) 118-124
21. Rascol O., Goetz C., Koller W., Poewe W., and Sampaio C. Treatment interventions for Parkinsons disease: an evidence based assessment. Lancet 359 (2002) 1589-1598
22. Ricaurte G.A., Irwin I., Forno L.S., DeLanny L.E., Langston E., and Langston J.W. Aging and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced degeneration of dopaminergic neurons in the substantia nigra. Brain Res 403 (1987) 43-51
23. Rousselet E., Joubert C., Callebert J., Parain K., Tremblay L., Orieux G., et al. Behavioural changes are not directly related to striatal monoamine levels, number of nigral neurons, or dose of Parkinsonian toxin MPTP in mice. Neurobiol Dis 14 (2003) 218-228
24. Rozas G., Lopez-Martin E., Guerra M.J., and Labandeira-Garcia J.L. The overall rod performance test in the MPTP-treated mouse model of parkinsonism. J Neurosci Meth 83 (1998) 165-175
25. Schlingmann F., Van de Weerd H.A., Baumans V., Remie R., and Van Zutphen L.F.M. A balance device for the analysis of behavioural patterns of the mouse. Anim Welfare 7 (1998) 177-188
26. Schroeder U., Kreutz M.R., Schroeder H., and Sabel B.A. Amphetamine induces hypermotility in MPTP lesioned mice. Pharmacol Biochem Behav 56 (1997) 281-285
27. Sedelis M., Hofele K., Auburger G.W., Morgan S., Huston J.P., and Schwarting R.K.W. MPTP susceptibility in the mouse: behavioural, neurochemical, and histological analysis of gender and strain differences. Behav Genet 30 (2000) 171-182
28. Simon V.M., Parra A., Minarro J., Arenas M.C., Vinder-Caerols C., and Aguilar M.A. Predicting how equipotent doses of chlorpromazine, haloperidol, sulpiride, raclopride and clozapine reduce locomotor activity in mice. Eur Neuropsychopharmacol 10 (2000) 159-164
29. Sonsalla P.K., and Heikkila R.E. The influence of dose and dosing interval on MPTP-induced dopaminergic neurotoxicity in mice. Eur J Pharmacol 129 (1986) 339-345
30. 2 agonists and antagonists on velocity of movement, rearing and grooming in the mouse. Neuropharmacology 25 (1986) 455-463
31. Stromberg U., and Svensson T.H. Differences between (+)- and (-)-amphetamine in effects on locomotor activity and l-DOPA potentiating action in mice. Naunyn-Schmiedeberg's Arch Pharmacol 287 (1975) 171-179
32. Sundstrom E., Stromberg I., Tsutsumi T., Olson L., and Jonsson G. Studies on the effect of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) on central catecholamine neurons in C57BL/6 mice. Comparison with three other strains of mice. Brain Res 405 (1987) 26-38
33. Thomas K.V., and Handley S.L. On the mechanism of amphetamine-induced behavioural changes in mouse: III. Effects of apomorphine and fla 63. Arzneim-Forsch/Drug Res 28 (1978) 993-997
34. Ushijima I., Mizuki Y., and Yamada M. Development of tolerance and reverse tolerance to haloperidol and SCH23390-induced cataleptic effects during withdrawal periods after long term treatment. Pharmacol Biochem Behav 50 (1995) 259-264
35. Van de Weerd H.A., Bulthuis R.J.A., Bergman A.F., Schlingmann F., Toolboom J., Van Loo P.L.P., et al. Validation of a new system for automatic registration of behaviour in mice and rats. Behav Process 53 (2001) 11-20
36. Vasse M., and Protais P. Increased grooming behaviour in induced by apomorphine in mice treated with discriminant benzamide derivatives. Eur J Pharmacol 156 (1988) 1-11
37. Vetulani J., Sansone M., and Oliverio A. Analysis of the difference in the behavioural effects of apomorphine in C57BL/6 and DBA/2 mice. Pharmacol Biochem Behav 7 (1982) 967-971
38. Vetulani J., Nalepa I., Antkiewicz-Michaluk L., and Sansone M. Opposite effect of simple tetrahydroisoquinolines on amphetamine- and morphine-stimulated locomotor activity in mice. J Neural Transm 108 (2001) 513-526
39. Willis G.L., and Donnan G.A. Histochemical, biochemical and behavioural consequences of MPTP treatment in C-57 black mice. Brain Res 402 (1987) 269-274